. Development of a flow cytometry-based potency assay for measuring the in vitro immunomodulatory properties of mesenchymal stromal cells. Immunology Letters, 177,[38][39][40][41][42][43][44][45][46] We conclude that this protocol represents a practical, quantitative assay of a clinically relevant functional effect of hBM-MSCs as well as other immunomodulatory agents.
Introduction
In the last decade, several studies have emerged demonstrating that autologous and allogeneic culture-expanded mesenchymal stromal cells (MSC) from different sources possess immunomodulatory properties [1] [2] [3] . It has been convincingly shown that such immunomodulatory properties of MSC play specific roles in the maintenance of peripheral transplantation tolerance, autoimmunity and tumour evasion [1] . The anti-inflammatory activities of both autologous and allogeneic MSC are being exploited clinically with administration of MSC now being used to treat or prevent a range of immune/inflammatory diseases such as Graft-versus-Host-disease (GvHD), inflammatory bowel disease, diabetes mellitus, multiple sclerosis, organ transplant rejection, myocardial infarction and stroke [4] [5] [6] .
Currently, there are at least 572 on-going clinical trials worldwide which aim to exploit the anti-inflammatory and immunomodulatory properties of MSC (www.clinicaltrials.gov). Global commercialization activities in the stem cells market have increased dramatically during the past decade with the establishment of several heavily capitalized companies focusing on MSC manufacturing and cryopreservation [2] .
As more individual MSC sources and products are developed and trialled as clinical products and as the regulatory framework for clinical trials of stem cell products continues to evolve, there will be a clear need to confirm and compare the potency of the immunomodulatory/anti-inflammatory effects of each product for optimal treatment of disease [7] [8] [9] .
The immunomodulatory activities of MSC in vitro have been measured on different immunological cell types, including T cells, B cells, NK cells and monocytes [10] [11] [12] [13] . Monocytes have critical roles in innate and adaptive immunity during infection and sterile inflammation and respond rapidly to activation signals via an array of pattern recognition receptors [14] [15] [16] . Monocytes circulate in the peripheral blood and upon stimulation, transmigrate into injured or infected tissues where they contribute immediately to early inflammatory responses and subsequently may differentiate into mature myeloid effector cells including macrophages and dendritic cells [17] . During inflammation, monocytes produce several key pro-inflammatory mediators including tumour necrosis factor alpha (TNF-), interleukin 12 (IL-12), interleukin 6 (IL-6) and monocyte chemo-attractant protein 1 (MCP-1/CCL2) [4, 14] . TNF- is involved in the pathogenesis of several diseases such as arthritis, sepsis, acute tissue ischemia, inflammatory bowel disease and GvHD. MSC administration could be used to decrease the severity of inflammation [18] [19] [20] [21] .
In this study we describe the development of a flow cytometry-based whole blood assay to screen for potency of human bone marrow-derived MSC (hBM-MSC) to suppress innate immune responses. A key goal was to develop an assay methodology with potential to be rapidly and practically employed in cell manufacturing facilities to allow for the optimal selection of MSC donors or at point of care to facilitate "personalized" matching of a cell product to each patient.
Methods

Optimization of monocyte activation to use by flow cytometry
Peripheral blood from a total 10 healthy adult volunteers ranging in age from 24- Then, cells were surface stained for 10 minutes at room temperature in the dark with the following monoclonal antibodies (all from eBioscience): CD16 FITC (clone eBioCB16), CD45 PerCP Cy5.5 (clone 2D1), and CD14 APC (clone 61D3). Following washing, fixation and permeabilization using the IntraPrep Kit from Beckman Coulter, cells were stained intra-cytoplasmically with PE labelled monoclonal anti-TNF- antibody (clone MAb11).
In some experiments, cells were labelled with PE-labelled anti-IL-12/IL-23 p40 (clone C8.6), anti-CCL2 (MCP-1; clone2H5) or anti-IL-10 (cloneJES3-9D7). Subsequently, samples were washed, resuspended in FACS buffer (1X PBS, 2% FBS, 0.05% NaN 3 ) and acquired using the BD Accuri C6 (Becton Dickinson) 4 colour flow cytometer. Data were analysed with BD CSample Analysis software (Becton Dickinson) or FlowJo version 10 (Tree star). As outlined in results, experiments were designed to determine the optimal conditions of anticoagulants, LPS dose, incubation time and blood dilution to use in the immunosuppressive assay.
For T cell activation, three activation protocols were used, namely i) PMA (5 ng/ml) plus Ionomycin (0.5 g/ml), ii) PHA (10 g/ml) or iii) anti-CD3 + anti-CD28 ®Dynabeads.
Calcium chelation and analysis of LPS surface binding
To determine the effect of calcium chelation, heparinized blood diluted 2 times was cultured for 4 hours with 0.6 g/mL Brefeldin A, with or without addition of 1ng/mL of LPS and in the presence or absence of 2mM ethylene glycol tetra acetic acid (EGTA, Sigma-Aldrich). After activation, cells were stained, fixed and permeabilized as described above. In other experiments 1x10 6 
Immunophenotyping
The immunophenotypic characterization of hBM-MSC was performed on the day they were used for co-culture. Using the human MSC analysis kit (562245) from BD Stemflow™, 2x10 5 cells were stained according to the manufacturer's protocol with antibodies against CD44, CD73, CD90, CD105, CD11b, CD19, CD34, CD45, HLA-DR and Propidium Iodide (Sigma-Aldrich). The samples were acquired in the BD Accuri C6 flow cytometer and analysed with FlowJo version 10.
Optimised immunosuppressive assay protocol
This assay is divided in 2 parts. Firstly, MSC were co-cultured with peripheral blood and then monocytes stained intra-cytoplasmically for TNF-α expression, using the same protocol as described above. To prepare the co-culture, peripheral blood collected as described above was diluted 10X with RPMI 1640 media (Gibco). To each well was added 50l of this diluted blood. Based on the average monocyte counts from n=10 donors, obtained using data from the Accuri C6 cytometer, this corresponded to 7,500 monocytes, a figure sufficient to obtain adequate events from subsequent flow cytometric analysis. The blood was cultured with 0.6g/mL Brefeldin A (eBioscience), with or without Ultrapure LPS-EB (InvivoGen) at 1ng/mL. hBM-MSC at passages P 2 -P 7
were added to the culture in different numbers of viable cells (2. 
Cell contact-dependence of Immunosuppression
To determine if MSC immunosuppression was contact dependent instead of using 96 round bottom plates we used 24 well plates with transwell inserts (Greiner bio-one ♯ 662 640). For these experiments, 4x10 5 MSC where placed in the bottom chamber with PBMC, LPS and Brefeldin A in the top chamber. Three separate experiments were carried out using 7 different healthy blood donors and 2 MSC donors P 2 -P 5 (n=10). To determine if supernatants from MSC had immunosuppressive activity, 3 different MSC preparations were seeded in 6 well plates (4x10 5 MSC/well) for 48 hours in the presence or absence of LPS (1ng/mL) and supernatants collected and added to the whole blood assay.
Statistical analysis
Results are expressed as average and standard deviation of percentage of TNF- production by monocytes, using Microsoft Excel. To determine the statistical significance of the differences observed between different conditions, paired parametric t-Tests were performed, using GraphPad Prism software (version 6, San Diego, California, USA). Statistically significance differences were considered * when P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 .
Results and Discussion
Optimization of monocyte activation
Monocytes within whole blood cultures were distinguished from other PBMC by a combination of CD45 and CD14 staining ( TNF- was chosen for the readout because the kinetics of production following activation is extremely rapid [24] . In addition, TNF- is an important cytokine that is involved in the regulation of a wide spectrum of biological processes and regulates the immune response by activating cell proliferation, receptor expression, and migration. In addition, TNF- has been shown to regulate the production of other cytokines [4] . In the context of the therapeutic use of MSC, important immunosuppressive activities of MSC are mediated via the TNF/TNFR [18] [19] [20] . This emphasizes the potential of MSC to modulate inflammatory lesions such as GvHD and inflammatory bowel diseases.
In order to optimize the assay, variations of multiple parameters were investigated to determine optimal efficiency and sensitivity. To optimize intracytoplasmic accumulation of TNF- protein, Brefeldin A was added to cultures.
Brefeldin-A inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus. Results indicated that concentrations from 0.6 to 3.0g/mL did not significantly alter the proportion of monocyte expressing TNF- and their staining intensity was indistinguishable (data not shown). Therefore, 0.6g/mL was used for all subsequent experiments. It should be noted that monocyte viability, determined by Propidium Iodide exclusion, was not compromised during the assay.
Next, blood was collected in three different anti-coagulants, namely sodium heparin, K 2 EDTA and sodium citrate, diluted 5X in RPMI and the % TNF- + monocytes quantified following 6 hours stimulation with 1ng/ml LPS ( Supplementary Fig 1) . [25] .
Dilution of whole blood prior to addition of LPS was found to significantly enhance the sensitivity of the assay as reflected in the proportion of monocytes staining positively for TNF- for a given concentration of LPS ( Supplementary Fig. 3 ). Thus at a 5X dilution of blood in RPMI, heparin and sodium citrate but not EDTA resulted in optimal stimulation (Panel A). However, when blood was diluted 10X, optimal stimulation was achieved in all three anticoagulants (B). The most likely explanation for these results is calcium availability. Thus, the serum calcium concentration (0.85-1.05mg/mL) will be further reduced in the presence of either citrate or EDTA anticoagulants [26] . However, EDTA is a more efficient calcium chelator [27] . Dilution of the blood in RPMI 1640, in which the calcium concentration is 100mg/mL, will saturate the calcium chelating activity of the added anticoagulants and therefore at a 5X dilution monocyte activation is achieved in citrate but not in EDTA. At a 10X dilution, the chelating capacity of available EDTA is also compromised and the free calcium concentration becomes sufficient to activate monocytes.
Thus, one of the most critical parameters that we identified during the optimization phase of assay development was the type of anti-coagulant in which blood was collected. As has been previously reported, the selection of anti-coagulant may significantly impact the accuracy of whole blood-based diagnostic tests for hematologic disease since different anti-coagulants have varying effects on blood cells for immunophenotying, morphology or other parameters [28] . Indeed, in a recent publication by Duffy et al. [29] where multiple stimuli were used in a human whole blood assay to standardize stimulation systems and define boundaries of a healthy human immune response, the three anticoagulants used herein were also tested. Duffy and colleagues also found that activation by a multiplicity of stimuli, including bacterial, viral, cytokine, TCR and microbial-associated molecular patterns (MAMP) were optimally achieved when blood was collected in heparinized tubes. However, these authors made no further comments on this finding.
Based on the combined results to this point and on the previously unappreciated calcium dependency of LPS-stimulated TNF- production, heparin was used preferentially for anticoagulation, the LPS concentration was fixed at 1ng/mL and whole blood diluted 10 fold in RPMI. The optimum time for LPS stimulation was determined to be 4-6 hours ( Supplementary Fig. 4 ). Note that after 8-24 hours, some degree of spontaneous TNF- expression was seen. Blood could be collected in heparin and stored at ambient temperature for 3 days and used successfully in the assay ( Supplementary   Fig. 5 ). As an alternative to TNF- expression, IL-12 ( Supplementary Fig. 6 ), MCP-1 and IL-10 (not shown) were assayed. As confirmed by intra-cytoplasmic staining (data not shown), production of IL-12 by activated monocytes was delayed compared with TNF-.
In addition, there was considerable variability in the proportion of IL-12-expressing cells ( Supplementary Fig. 6 ). Therefore, to shorten the duration of the assay and to maintain reliability, TNF- production only was monitored. Regarding to MCP-1 and IL-10, it was not possible to have reproducible MCP-1 and detectable IL-10 expression using intracytoplasmic expression and flow cytometry (not shown).
T cell stimulation assay
In parallel with studies investigating the quantitative inhibition of monocyte activation by MSC, studies were also carried out on T cells. (Fig. 2C) . As expected, MSC had a mean FSC (a parameter related to relative cell size) value 2.06 times (7.24/3.52) that of MM cells (Supplementary Figure 11) . In titration experiments, (Fig 2 B and C) , 5x10 5 MM cells did not inhibit monocyte activation already seen using 10-fold fewer, namely 5x10 4 MSC making it unlikely that cell size alone was responsible for inhibition. This is a short-term (6 hour) assay in 1ml
cultures in round-bottom plates; metabolic arguments are unlikely to be an explanation for the inhibitory effects of MSC on monocyte activation. As a positive control for inhibition, dexamethasone was used. As shown (Fig 2D) , a dose-dependent reduction of monocyte %TNF- expression was observed and was maximal at 10ng/ml dexamethasone -a concentration that was subsequently used in all experiments involving hBM-MSC. As an additional positive control, the hBM-MSC line TERT was used.
As shown (Fig 2E) , addition of 5x10 5 TERT cells to the whole blood culture inhibited monocyte activation. Since TERT cells were routinely available, they were used as cellular positive control in all assays.
Monocytes that had been pre-activated by LPS for 1 hour prior to MSC addition were also susceptible to inhibition of TNF- production (data not shown). Control experiments where monocytes and allogeneic hBM-MSC were co-cultured in the absence of LPS stimulation did not result in any TNF- expression by monocytes (Fig 2E) .
Taken together, this indicates that monocyte inhibition is MSC-specific, there is no reports [30] , we observed some variations in MSC potency (Fig. 3) . Ongoing clinical trials in which the potency assay is being used will attempt to correlate in vitro results with clinical outcome.
Mechanism of action of MSC
Given that MSC inhibited monocyte activation in a dose-dependent manner, we wished to investigate their mechanism of action. One possibility was that MSC in the whole blood culture would remove sufficient LPS so that monocyte activation would not occur. Therefore, we used biotinylated LPS to stain PBMC and MSC as well as cells in the whole blood assay. The biotinylated LPS used was as biologically active as the unlabelled material (not shown). As shown in Fig. 4A , LPS bound to monocytes in PBMC preparations (solid line) and addition of MSC reduced staining slightly (dotted line). As shown in figure 4B , LPS did not bind to MSC (solid line) even in the presence of PBMC (dotted line). T cells in the same PBMC preparation did not bind LPS ( Supplementary Fig   2E) . Thus, sequestration of LPS by added MSC was not the cause of reduced monocyte activation.
Release 
Conclusion
Using one of the best-described immune-modulatory activities of MSC, we were able to develop a simple, rapid whole blood quantitative flow cytometry based assay with which to measure their potency. The process of developing the assay conditions also highlighted the importance of considering a range of key technical variables and carefully optimizing each of these. Currently, MSC preparations are being supplied commercially for infusion into patients for a variety of diseases. However, to our knowledge, the only other MSC potency assay so far described measures cytokine release by activated blood cells [8] . This is a more time-consuming and expensive assay than the one described herein. Thus, the whole assay from blood collection to obtaining results, takes only 8-9 hours. The rapidity of this assay therefore has the potential of 
